VOL.

19

NO.

CHEMOTHERAPY

4

CLINICAL

TRIAL

WITH

311

A NEW

ANTICANCERAGENT,SOEDOMYCINTETSUOKITAHARA,SHIZUOHOMMAand NORIHISASATO
Tokyo Teishin Hospital, Surgical Division
MOMOESOEDA
II nd Research Institute, Research and Development H. Q.,J.D.A.
HIROSHISUMIYAMA
Pharmaceutical Division, Hitachi Chemicals(Received March 2, 1971)
Introduction
It has been shown that the host defence mechanism(immunity) plays an important role in the curative
process of malignant tumors in man and animals.
A close relationship between neoplastic changes andpre-existed deficiency of the immune response in thehost8,3), or between the oncologic actions of various
carcinogens and their inhibitory
effects upon the
immune response of the host10-12), or between thecompetence of the host to elicit immune response
and tumor regression14,17,13) has been demonstrated
mainly by animal experiments.
The improvementin therapeutic effect may be induced by addition of
immunotherapy to surgery and postoperative chemotherapy13,22), and an immunosuppressive
agent,
cortisone, is well known highly to reduce the chemotherapeutic effect of various anticancer agents",20,21).
It increases the incidence of metastases of malignant
tumors18,23). On the other hand, immunosuppressive
drugs are known to induce immunologicaltolerance34-27) and to suppress rejection reaction in man
and animals28-32). Immunological deficiency or induction of immunological tolerance may provide a favorable condition for neoplasia or progressive
growthof neoplastic tumors33-36).
Many types of anticancer agents such as alkylating
agents,antipurines,
antifolicacids, halogenatedpyrimidines, vinca alkaloids, and steroids have beenshown to be potent inhibitors of the immune response
in animals37-41) and in Mari42-44,46).
For these reasons, it seems paradoxical

to treatpatients with malignant tumors with chemotherapeutical agents which induce significantly
deleterious
effects upon the immune response of the host essential for the defence against tumor growth.
A new anticancer agent, soedomycin, has a uniqueproperty to suppress the nuclear division of tumor
cells and to induce the loss of viability of ascites
tumor cells such as EHRLICH ascites carcinoma,
Sarcoma-180, and YOSHIDAsarcoma, without causing
any injurious effect upon the cells of organs andtissues, including
the bone marrow,
lymphatic,
cardiovascular,
urogenital
systems,
liver, gastrointestinal tract etc.
Clinical trials were initiated in September, 1965,
mainly in order to evaluate its preventive effect upon
the recurrence of gastric cancer after radical removalof the parent tumor.
Total 83 patients were thus
treated until September, 1970, of which 72 cases
were patients with gastric cancer and 11 cases were
those with cancers of the other organs.
In this paper we will report the therapeutic
results obtained from patients treated for past 5
years.
I. Soedomycin
This agent was chemically extracted by SOEDA
from culture media of Streptomyces hachijoensis in
1963, and then purified and named soedomycin in
19651,2,3). It is now obtained in the form of white
amorphous powder, highly soluble in water, but
hardly soluble in ethanol or methanol.
Accordingto the data up to date, it seems to belong to polysaccharide having a molecular weight of about 1, 000,
and it shows a clear maximum absorption at 210 mit
on the absorption spectrum.
The LD,0 of this agent for the mouse of dd-strain
is more than 120 mg/kg by intraperitoneal
route. It
has neither myelotoxic nor lymphotoxic effect upon
animals and man.
It does not induce leukopenia,
lymphopenia, anemia, thrombocytopenia,
dysfunctionof the liver, gastrointestinal
toxic symptoms etc.
The red blood cells, hemoglobin and hematocrit are

CHEMOTHERAPY

312

rather increased by administrationof a daily doseof 5.0mg/kg of this agent to the rabbit for 14 days.
Histological examination of animals thus treated does
not reveal any toxic changes in the bone marrow,
lymphatic
system,liver,
kidney,cardiovascularsystem, lung, adrenal glands, gastrointestinal
tract,and other organs.
For clinical purpose, a daily dose of 1.0 to 2.0
mg/kg is usually given i. v. for at least 3 weeks
starting immediately after radical resection of the
primary tumor. In cases wherein radical resection
is incapable or in inoperable cases a longer coursewith a larger daily dose of soedomycin is usuallyrequired.
In spite of the complete absence of serious toxic
side-effects, soedomycin is capable of inducing inhibition of nuclear division of ascites tumor cells of
EHRLICH ascites cancer, Sarcoma-180 and YOSHIDA
sarcoma. For instance, the nuclear division rate of
YOSHIDA sarcoma cells drops, on average, to about
a half 6 hours after i.p. injection of O.2mg/kg into
the rat developing typical ascites tumor. This effectis usually maintained at least for 15 hours.
With
1.0mg/kg,
it drops to about 30% and persists for
24 hours.
In vitro treatmentof these ascites tumor cellswith this agent easily results in the loss of viabilityof such cells, which become incapable of inducing
ascites tumor if i. p. inoculated into susceptible
animals.
It is of much interest that animals once received
transplantationof ascites tumor cells treated, invitro, with soedomycin acquire a certain degree of
specific resistance within 10days sufficient to tolerate
i.p. inoculation of 10' to 10° intact tumor cells,
which correspond to 103 to 104 times the minimaltransplantable
cell dose1,2,3). Inoculation of as few
as 10 tumor cells is lethal to most WISTER rats.

JULY

1971

ranges between 40 and 60%, and usually 50% of allcases of gastric cancer4), so that the survivors of
5 years duration
cannot exceed 20% of the total
cases of gastric cancer.
Since it is paradoxical to expect a success inchemotherapy of more advanced cases wherein only
subtotal resection of tumor is possible or inoperable
at all with the same agents incapable of inducing
complete cures in almost all radically operable cases,
chemotherapy with soedomycin was applied mainly
to the patient with gastric cancer whose primarytumor had been radically removed. (Group 1).
Postoperative chemotherapy should, of course, be
started immediately after operation to eradicate theresidual remnants of cancer cells within the period
where the number of such cells is quite small. In
our series, 67 cases were treated immediately after
operation,
but there were 5 other cases whereinchemotherapy was started several weeks or months
after operation done in other hospitals (Group 2).
A-1.
Patients in Group 1
The age and sex distributionsof total 67 cases
are shown in the following table (Table 1).
Table

1.

Age

and sex*(2) means that 2 patients
December 1970.

distributions

died up to the end of

The classification of total 67 cases due to the stageof gastric cancer is shown in the following table(Table

2).
Table

2.

Stage

distribution

Although its antitumor activity is not so potent,soedomycin may be a unique anticancer
agent ofmuch higher selective toxicity than any other anticancer agents commonly used at present for clinicalpurpose.
II.

The object of clinicalA.

Gastric

cancertrial

patients

The 5-year-survival
rate of patients with gastriccancer whose primary cancerous lesions have beenradically resected is around 30% according to thestatistics of many authors5-7). The rate of patientswherein such radical resection can be performed

The classification
tive course-lengths(Tableof 67 cases due to the postoperais shown in the following table

3).

A-2.
Patients in Group 2
Five cases included in this group did not receive
immediate
chemotherapy
with soedomycin after

VOL.

19NO.

CHEMOTHERAPY

4313

operation, because they had received radical operation in other hospitals.
A period between 8 weeks
and 10 months had passed after operation before
they received chemotherapy with soedomycin in our
hospital.
According to the statistics of radicallyoperated cases of gastric cancer, more than 20%
of patients are known to develop recurrence
anddie within a year after operation.
In view ofthis fact, the residual remnants of neoplastic cells
may grow relatively rapidly after surgical enucleation of the parent gastric tumor.
These cases inour series, therefore, have been followed up asa different category from that of the Group 1.
In this group, 35, 26, 15, 8 and 7 months
have

these 11 cases until the end of December 1970.
III.
Analysis of the therapeutic
results
A. Patientswith gastric cancer
A-1.
Group 1 (67 cases)
In this group, 5 cases developed recurrence
anddied during the period between 16 and 26 months
after operation.
No death occurred within a year
among total 55 cases wherein more than 12 months
have passed since they received radical operation in
our hospital.
The 2 and 3-year-survival
rates atthe end of December 1970, in our series are 93. 6%(44/47) and 88. 9% (24/27) respectively which are by
far better than those in any other previous series
reported by many authors").
Five out of total 67 cases in this Group 1 expired
due to recurrence,and the last death occurred 26
months after operation. Since then there has beenneither recurrence nor death among total 42 cases
who have survived more than 2 years without signsof recurrence since they received radical resectionof the parent tumors.

passed respectively
since they received operation,and neither recurrence nor death has occurred until
the end of December 1970.
B. Patientswith other cancer
This group is consisted of total 11 cases of cancerof the various organs other than the stomach. There
are 6 cases of colon cancer, 2 cases of rectal cancer,
2 cases of breast cancer, and one case of cancer of
the thyroid gland. One of 2 cases of breast cancer
was surgically treated in other hospital, so thatchemotherapy with soedomycin was initiated about
2 months after operation.
The other 10 cases wereoperated in our hospital and followed by immediatechemotherapy with soedomycin.
The classification of 11 cases due to their diagnosis
and postoperative course length is seen in the following table (Table 4).
Neither recurrence nor death has occurred among
Table

3.

In many other previous statistics,
the number ofsurvivors progressively decreases as time goes byduring the course between 2 and 5 years after operation. For instance, the 2, 3, 4 and 5-year-survival
rates in the URABE's series5) are 57. 2%, 44. 4%,
35. 5% and 32. 2% respectively,
while the 2, 3 and4-year-survival
rates in the KURU's series7) are
50. 6%, 42. 5% and 31. 9% respectively.
The survival rates in our series are shown in thefollowing table (Table 5)
In our series, there are total 61 cases wherein

Postoperative

course-lengths* 10(1) means that a period between 42 and 47 months
cases and one of them died already.
Table

4.

Classificationhasof 11 cases

passedpostoperatively

in 10

CHEMOTHERAPY

314

Table 5.

The survival

JULY

1971

rates in the Group 1 (in December 1970)

more than .6 months have passed since they received
operation. As shown in Table 2, the rate of patients
surgically treated at the stage I in our series wasover 40%.
the rate of such patientsis usuallyless than 20%4). Thus in the URABE's series, it wasless than 3% (3/124), while in the KURU's series7
It was 21. 5% (165/768).
In the YAMAGATA'sseries6) and INOKUCHI's series4) it was 10.6%(57/533)

and 16.7% (62/371) respectively.
Consequently, this high rate of the stage I may
have apparently contributed to an excellent resultin our series, however, the 2 and 3-year-survival
rates of the stages II and III in our series are 88. 9%(4/27) and 76.9% (10/13) respectively. Thesetgures are much higher than those in any otherseries mentioned above. For instance, the 2 and 3year-survival rates in the KURU's series7)were
40. 0% (175/437) and 30. 9% (81/262) respectively.
According to the previous statistics, the 5-yearsurvival rate of the patient surgically treated at thestage I is generally high and 22/22 or 100% in the
INOKUCHI'sseries4, 2/3 in the URABE'sserieso, 30/33
or 90. 9% in the YAMAGATA'sseries6), or 66. 0% in
the TAGUCHI'sseries16). KURU7)did not show the
5-year-survival rate in his series. (The 4-yearsurvival rate in his series was 23/27 or 85. 2%).
The 2-year-survival rate of the patient surgicallytreated at the stages II and III was shown to be
69/121 or 57. 0% (5), 253/496 or 51. 0% (6) , and175/437 or 40. 0% (7), while 3-year-survival rateof such cases was 53/121 or 43. 8% (5), 165/461 or
35. 8% (6), and 81/262 or 30. 9% (7) respectively.
Similarly, the 4-year-survival rate was 42/121 or
34. 7% (5), and 23/117 or 19. 6% (7), while the 5year-survival rate was 38/121 or 31. 4% (5), and73/417 or 17. 5% (6) respectively. For unknown
reasons, NAKAZAT01.5)
and TAGUCHI")did not show
the exact 3, 4 or 5-year-survival rate in their series.
In contrast, neither recurrence nor death has

occurred among total 28 cases in our series wherein
operation was performed at the stage I of gastriccancer.
Thus the 3, 4 and 5-year-survivalrates
are 14/14, 5/5, and 1/1 respectively.
With regard to the stages II and III, the 2, 3, and4-year-survival
rates are 24/27 or 88.9%, 10/13 or
76.9%, and 2/2 respectively
in our series, which
are much higher than those in the other series cited
above.
With regard to the overall survival rate, 33 outof 124 cases in the URABE's series (26. 2%) and
244 out of 768 cases in the KURU's series (31. 8%)
died within a year after operation, while 243 out of
553 cases in the YAMAGATA's series (43. 9%) diedwithinone and a half years following operation. In our series, none of the total 55 cases
died within a year following operation, and all
survived more than one year, regardless of the stageof the disease. This may be an outstanding featurein our series.
Total 42 cases in our series have survived morethan 2 years without
any signs of recurrence.
Neither recurrence
nor death has occurred sincethen among these 42 cases, and 2, 5 and 17 cases
have survived more than 5, 4 and 3 years respectively, all in good health. This long durable savingfrom recurrenceof the disease may be anotheroutstanding feature in our series.
Five cases developed recurrence
and died during
the course between 16 and 26 months following
operation, 2 were surgically treated at the stage II
and 3 at the stage III, however,
7 out of 8 cases
operated at the stage II or III have survived morethan 3 and a half years in good health since theyreceived operation.
Although the number of cases in our series is not
sufficient as yet, it may be evident that soedomycin
chemotherapy given immediately after radical operation may have much contributed to inhibition

VOL.

19

NO.

of postoperative
A-2.

CHEMOTNERAPY

4

recurrenceof gastriccancer.

315

from chemotherapy

of gastric

Gastric cancer in the Group 2

As mentioned
above, 20 to 30% of radically
Operated cases of gastric cancer cannot survive
one year following operation. This fact may meanthat the residual remnants of cancer cells after
surgical removal of the parent tumor may growrelatively
rapidly withinseveralmonthsafter
operation and cause early death of the patient.
Postoperative
chemotherapy
should, therefore,bestarted as early as possible after operation in orderto eradicate such remnant neoplastic cells when
they are quite small in number.
Five cases in this group were given

soedomycin

cancer.

Discussion
For many years, it has been a failure to induce
complete relief even in most cases of cancer whereinradical resectionof the primarytumor can be
performed.
In gastric cancer,
more than 20%,of such cases will develop recurrence
and die
within a year following radical removal of theparent tumor, whether they are given postoperative
chemotherapy or not. In general, more than 50%of them cannot survive 3 years, and the survivorsof 5-year-duration
cannot exceed 30% of radicallyoperable cases. The rate of such radically operable
cases is, on average,
50% of all patientswithafter the course of 8 weeks to 10 months since they
had received operation in other hospitals.
There
were no signs of recurrence when chemotherapy
with soedomycin
was started,
however,theirfurther courses have been followed up included ina separate group from the Group 1, wherein chemotherapy with soedomycin was given immediately
after operation, because the conditions under which
they first received out chemotherapy might be substantially different from those of the Group 1.
In spite of delayed application of soedomycin
chemotherapy, they have been quite well, and 35,

gastric
5 years

26, 15, 8 and 7 months have passed respectively
since they received operation. No signs of recurrence
have been observed in these cases up to the end of
December 1970.
B. Patients with other cancer

gastric cancer.
It is, of course, far more difficult

As shown in Table 4, there are 6 cases of cancerof the colon, 2 cases of cancer of the rectum, 2cases of cancer of the breast, and one case of cancerof the thyroid gland. Except for one breast cancer
case, they received radical operation and immediate
postoperative chemotherapy with soedomycin in our
hospital.
One patient with breast cancer received
operation in other hospital and chemotherapy withsoedomycin was started about 2 months later.
More than 3 years have passed in 6 out of 11
cases in this group without any signs of recurrence
since operation was performed.
Besides these, 2cases of colon cancer and one case of rectal cancer
have survived more than one year in good health.
Although the number of cases in this group is too
small, it still appears thatchemotherapy
withsoedomycin may have contributed to inhibition of
postoperative
recurrence
at least of cob-rectal
cancer, considered in light of the data obtainedcancer, so that the rate of survivorsofduration is less than 20% of the overallcases of this disease).
For this reason,much effort has been made foryears effectively to suppress postoperative recurrence
and thus substantiallyto improve the survival rateof the patient by means of chemotherapy
withvarious anticancer drugs, but no significant successhas been achieved up to the present time. Moreover,in some statistics it appears that the present chemotherapy routinely applied in our country may help
rather than hinder the postoperative
recurrenceof
to attaincom-

plete relief of gastric cancer, wherein only subtotal
resection of the parent tumor is possible or whichis inoperable at all.
It seems entirely impossible
to achieve a success in inducing cures of long duration in such cases by means of chemotherapy with
anticancer
agents incapable of inducing completecures in almost all cases of radicallyoperable
gastric cancer.
It is well known that all or most anticancer agentsclinically used at present are potent inhibitors of
the immune response in man27,42-44,46) and animals37-41,45). It has been demonstrated that inhibitorsof the immune response of the host may induce
immunological toleranse to various antigens including allografts
in adult animals24-26, 41,47) and inman27-30,47). In human transplantation
surgery,immunosuppressive
drugs suchas azathioprine(Imuran), 6-mercaptopurine,
prednisone, and dactinomycin have been used to suppress rejection reactionof the recipient28-30). Clinically, carcinoma metastaticto the kidney was transferred to the recipient when
he received a kidney transplantfrom a cadaveric

CHEMOTHERAPY

316

JULY

source28-80). The tumor persisted
and grew while
the recipient received immunosuppressive
therapy,
but underwent
immunologic
rejection when theadministrationof immunosuppressive
drugs wasdiscontinued
and the major portion of the tumor
was removed30).
Transplantationof human celllines from man to man usually does not occur andcells are rejected promptly in healthy recipients28,48,49), but it was demonstrated that human tumors canin mice33,34),

while

was

by antilymphocytic

inducedtreatment23)

thatfacts,

2 typesof actions

effects

animalexperiments.
inhibition

anotheris thebe serially maintained in cortisone-treatedlaboratory
animals such as hamsters,
rats, and mice",51).
These studies have emphasized the importance ofthe host's immune response
in determining
thebehavior of allogeneic transplanted
tumor in man,and these findings may suggest that the immune
mechanism may be operating in spontaneous
neo-of theimpairedplastic growth in man, at least in those tumors that
may have specific antigenic components.

regression

According to the opinions of RUBIN") and BURNE36),
it appears that the induction of immunologic toler
ance or the existence of immunologic deficiency may
always provide a favorable condition for neoplasia
or progressive growth of neoplastic tumors.

fundamental

In experimentalof thedrugs

thepotentinduceof theSoedomycin

theimmunologically

impairedthegrowththeimmunologicalofisneither
inducedoxan),

methotrexate,

increase

such

that

immunosuppressive

as cyclophosphamide(en-and 5-fluoro-2-deoxyuridine

the incidence of chemicallyinduced tumors

thrombocytopenia,

seen

these,
growthascites

cancerinducesofexperimental

sarcoma.

S-180, or

chemotherapy

to theofbemeasurestumorstumor,

anticancer
sizeof successshouldtherapeutic

it therapeuticallyor solid

inversely
proportional
55-57), the first stepwithfor clinicalor solidoftreatedused

ascites

effectand alopecia

patients

routinely

Despitetheimpairement

disturbance,

among

drugs

as EHRLICH'S

human

of

upon normal

not

of

the

effectIt

ipractice.

Since

cells

response

does

anticancer

YOSHIDA'S

neoplasticItsignificant number of animals.
Based upon thesefindings they suggested
that the effective therapy
would depend upon the availabilityof agents sufficiently selective to inhibit the growth of the tumor
without impairing the immunologic response of the
host.

such

the

host.

gastrointestinalntosufficiently

theinfrequently

nhibitioinlymphotoxic.

of the liver,

other

of

no harmful

anemia,nottheaccordingto inhibit

tissuesofresultdependent

an agent

impairing

leukopenia,

observedout

without

WHICH") found that the therapeutic treatment aloneor the host immunologic reaction alone was unable
to cause complete regression of tumors. In contrast,
the combination of these 2 factors led to cures in a

drugs

may

selective

nor

REINER et al.

which

to obtain

It induces

anti-

deleterious

tumor.

foundprinciple

humansuppression

host,

was

of
known

with

of the
of

and

and

regression

hitherto

toinhibition

organstumor

chemotherapy

associatedresponse

the host.

intherapeuticallyof theinevitably

myelotoxic

anticancer

thedependent

tostudies with S-180, FERRER and

GLYNN et al. treated CDBA F1 hybrid male micebearing advanced leukemia L1210 with halogenatedderivatives of methotrexate and obtained an extensive
increase in survival time and appreciable numberof survivors of indefinite duration. However, manyof these survivors were shown refractory to reinoculation with either antifolic-sensitiveor resistant
sublines of leukemia L 121052,53). Thus, increasedcures of animals by halogenated methotrexate
was
attributed
to the elicitationin the host of an
immune response which contributed to the inhibition of growth of leukemia L 1210.

is

growthincancereffects

for theseen

tumor.

difficulty

may be attributed

immuneto con-responsible

chemotherapy

immunologicallytheresonable

are

One

cancerside

systems.

it seemsof anticancer

inducedof metastases

serum54) or cortisone

tumor

of theseoverallThus,

enhancementin murine

In view
sider

the

1971

the

tumor

is

mass'8,in chemotherapy
discovery

completely

to

of

of

chemo-

suppressthepostoperative
recurrencein the radicallyoperablecases
of cancer.
It seems
quite
paradoxicaltoexpecta therapeuticindefinite

durationpatient,
removedwherein the cancer lesion has been partiallyor inoperable
at all, withan anticancer

agent

ineffective
cases

radically

removed.
thesein whichreasons,

cases

of gastricweretreated

after

they

in obtaining

in inducing

or mostFor

successin an appreciable

with
had

completethe cancer

totalcancerofof thecures

in allhave

been

lesions

83 casesconsistingof 72

and 11 casesof othercancersoedomycin
received

curesnumberasradicalearlyaspossible

resectionof the

VOL.

19

NO.

4

CHEMOTHERAPY

317

parent tumors.
The results obtained in our series
have been significantly
better than those in any
other series reported by many authors, wherein nohealthforTheremaining

18

cases

have

been

also

well

months

quite

free

from

any

signs

of

postoperative chemotherapy was given5) or similar
postoperative chemotherapy
was given with mitomycin C, endoxan, toyomycin, and 5-FU7,15,16).
In general, more than 20% of radically operable
cases of gastric cancer developed recurrence
andexpired within a year after operation5-7), while
none of the total 58 cases in our series expired
during the course of one year following operation.
This is one of the outstanding
featuresin ourseries.
It may be extremely difficult to expect anextensive increase of survivors of 5-year-duration
by means of chemotherapy with anticancer
agentsincapable of suppressing postoperative recurrence inall or most radically operable cases for as short asa year following operation.
Even in the cases operated at the stage I, the 5-

rence.

This

long

durable

these

cases

year-survival
rate was reported as low as 63% in
the series given no chemotherapy
or 66% in theseries postoperatively treated with mitomycin C16).
In our series neither recurrence
nor death has
occurred among total 28 cases operated at the stage
I for post 62 months since September 1965.
Five cases of gastric cancer operated at the stage
II (2 cases) and III (3 cases) in our series expired
due to recurrence
during the course of 16 to 26
months since they had received operation in our
hospital,
but the remaining
67 cases have beenquite well without any signs or symptoms of recurrence.
The 2-or 3-year-survival
rate of the cases ofgastric cancer in our series operated at the stage
II and III is 24/27 (88. 9%) or 10/13 (76. 9%),at the end of December 1970.
These figures aremuch higher than those in the statistics cited above.
For instance, URABE et a15) reported that these were
57. 0% (69/121) and 43. 8% (53/121) respectively,
and KuRU7) showed that these were 40. 0% (175/437) and 30. 9% (81/262) respectively.
NAKAZAT015)
reported that the 2-year-survival
rate in his series
postoperatively treated with a full course of 40 mgof mitomycin C was 73. 7% (84/114), but he did notshow the 3-year-survival
rate of that series.
There are total 42 cases of gastric cancer operated
at various stages in our hospital, who have survived
more than 2 years without any signs or symptomsof recurrence.
It is much noteworthy that among
these cases recurrence has never developed thereafter, and 17, 5 and 2 cases have been in good

to

35

seen
in

in

more

our

series.

Total

11

the

cases

stomach

In

6

out

than

3,

of

and

cancersimilarly

thesecases,

in

other

with

soedomycin.

than

since

radicaloperations

5 caseshaveremaining

signs

of

the

numberThus,although
is

that
a

not

the

so

effective

agent,

suppression

cantlyimproved

patient

withparentthedatagrowing

gastric
been

thesimilarinthepatient

withpartially
report

later

cases

of

near

other

of

now,

on

On

signifiof

cancerthewhosegastric

orinoperable

separately

fromcancer

which

the

the

on

other

to

thus

operated.

whereinor

clear

contributed

cases

removedgastric

ourbeprognosisorfuture.

in

may

and

radicallycancer,been

soedomycin,

much

recurrence

progressively

reportitpostoperative

had
of

have

patients

with

has

of

either

tumor

The

of
present,

treatment

anticancer

years

recurrence.

atpostoperative

new

are

sufficient

3

than

more

The

seriesfeatureorgansrecurrencenorecurrencethewithout

25

recur-

treatedperformed.
with

for

outstanding

were

well

respectively.

from

anotherpassedalso

5 yearssaving

is

were
of

4

we

will

details

of

tumor
at

the

was

only

we

will

all,

radically

operatedcancer.

AcknowledgementThe

authors

Director

of

deep

are
IInd

much

indebted

ResearchtoInstitute,interest

andheplful

advicein

SOEDA,

M.:

Studiesonaanti-tumor

Dr.

K.

KAMIKO,

J. D.

A.,

for

this

work.

his

References1.

soedomycin,
Acta
2.

Acta

26:

1483-1491,

M.:

Studiesona newanti-tumor

Radiol.

26:1492-1501,

M.:

Studieson

ReportNo.

5.

INOKUCHI,

K.

No.

3-9,

2211,

URABE,

Clin.

1967.
activity
agent.

of

Nippon1967.
antitumor

Defenseimmunity:
Med.

J.

14:

1•`

10:

1964.

7.

KURU,

M.:

8.

BERENBAUM,
immunePREHN.

FURUSAWA,

M.:

Jap.

Med.

J.

1965.
YAMAMOTO,S.

YAMAGATA,

164,

&

M.,

374,

9.

Natl.

of
Nippon1965.

TAKEMORI,

6.

4.

activity
agent.

anticancer

SOEDA,

6,
4.

anticancer

Radiol.

SOEDA,
soedomycin,

3.

new

&

K.,

MIURA,

791-799,

R.,

Jap.

J.

CancerJ. Cancer

Clin.

10:

370-.

2262,

3-6,

1967.

1964

S.:

Jap.

Jap.

Med.

J.,

C.:

Effects

M.

TAKANO,S.:

process.

Brit.

No.
of

Med.

carcinogens
Bull

20:

on
159〜

1964.
R. T.:Functionofdepressed

immu‑

CHEMOITHERAPY

318

nological,reactivity

Natl.
10.

CancerSTJERNSWARD,
barrierduring

Inst.
J.:

and

37:
11.

on

on

a

tumor-host

rejection24.

induced
of

Natl.

R.

S.

Cancer&reterologous

tuberclebacilli.

II.

Protection

isografts.

J.

Exptl.

Med.

ofpolypeptide
1963.

STEINKULLER,C.B.,

againstD.

W.:

Studiesonheterologous

26.

tumor

bacilli.

attenuated255-.-275,

S,.,
&

24

J. F.

tence

of

1967.

.

the

NAK,AZATO,

16.

TAGUCHI,

17.

MIHICH,H.:

MARTIN,Res.

D.

FUGMANN,S.,

MIHICH,70E.:600•`602,

1969.
in

in

22:
R.

size.

J.

H.

&

1962.
32.
host

Cancer

of

Res.

29:

Cortisone

N.

of

Y.

848-854,

andtissues

H.

33.

dif-

34.

Sci.

56:

resistance
in

Acad.

Sci.
D.

59:

S.,

to

cures
tumorsCancerRes.

70:

AGOSIN,M.,

CHRISTEN,NEGHEME,A.,,induced.

ofthegrowth

of

1955.
P. E.

&

FUGMANN,36.

ofspontaneous

murinewithsurgery,

combi-

and709-716,

35.

Ann.

37.

1970.
R.,

PIZARRO,metastases

BADNEZ,
0.

0.,

GASIC,&JARPA,

ofadenocarci-

A.:

38.

a

192:

rejection

of

renal

of

selected

production

in

J.

by

or

CancerInst.

RUBIN,

H.:

&

Y.

G.

&

immuneM.:

the

Effect38:

iso-inducedtumors

1966.
C.

M.:

Increased.

afterrecipientmice

753.759,

The

immunoby

metho-

Biol.

Immunologic
Lancet&adaptive

basis
Cold

27:

1:

J.

Natl.

for

non-

1967.

immunologicalF. M.:

ofgeneration

isotransplants

Quant.

SpringHarbor441-452,

1962.

aspectsof1171•`1174,

malig-

1967.

GOOD,R.:

Chemicalsuppres-

immunity.

Advan.

Immunol.

1967.
G.

antibody
orC.

SOUTHAM,

Stump.

91,...,229,

V.

5-fluoro-2-deoxy-uridine.

GABRIELSON,A.

N.

Cancer429-430,

BURNET,

SANTOS,

WONG,

chemically210:

sarcoma.

6:

agentsAnn.

primary

first

rous

of

SENSENBREN-

antimetabolites.

infection

sion

&

1964.

on

disease.

EngL

1965.

tumor

trexateJ. E.:
cancerNew

man.

SOUTHAM,ofC. L .,MURRAY,

cytotoxic

of

&

J.
of

H.

P. P.,NatureREINER,A.

Inhibition

of

mice.

1965.

human

CARBONE,

997-1001,

REINER,of

HAMPERS,&404-423,

man

F. E.

homograft.

allograft.

OWENS,

in

COOK,

1968.

W.,

F. M.,V.:

PETERSON,

renal

B.,

Effects

HERSH,

25:

E.

479-483,

114:

,

J.

1171-1173,

P.

nant

immunotherapy.

J..

MERILL,'J.

Sci.

ROSEN

J. R.,J. M.,

Acad.

&

in

1964.

Homotransplantaiton

Assoc.

antibody

16-22;

1965.

CORSON,G.

effect752-754,

HAGER,

L. I.:

The
response

carcinoma.

R. E.:SANTOS,

E.:

of

and

with

induced183:1682〜

FEI,

SMITH,

neoplasm278:

anti1965.

Drug

MCPHAUL,
J. S.,
J. W.:

suppression

cortisone

hosts.

394-400,

HAYWORTH,

Enhancedroleheterologous

chemotherapy;

Cortisone

A.,

Med.

growth742•`747,

immuneWILSON,

in

to

&

on

102:

HARVIN,transplantation

1969.

immunity

cortisone-treatedpossiblenationG.,D.

cellular

W.:

M.

mouse
pairedNatureM.

immunosuppressionin"Individuality
of

Acad.

The

tissuesmammarry

23,

W.:

overcoming

A.:

MCINTOSH,

toand

RUBINI,

Assoc.,

response

L 1210combining

271:

Am,

FREIREICH,E.J.:

Inst.

chemotherapy

leukemiatissue-loss

TOOLAN,

R.

C.,

Med.

342-343,

toleranceMed.

transplantationon

HAYWORTH,

Natl.

effects

Cancer
C.:

Ann.

Y.

D.

J

InadvertentRes.

againstfrom

MARTIN,Engl.

MARTIN,NER,

pyridoxine-

218-227,

A.

31.

1953.

N.

New

139:

of

DAMESHEK,LANDY,man.

J. Med.

thechemotherapy,

Combinedmice.

ferentials"

22.

H.,

6-mercaptopurine

Immunologic

1969.

mechanisms

Res.

tumor

immunity

human

R.

of

J. Am.

1962.

STOERK,

in1959.

LEVIN,

cadaver; 602-603,

70:

cancerhomogenous

21.

1683.

syntheticbytolerance.

a456•`461,,:

Specificto131•`139,&

HUMPHREYS,

30.

80

M.:

ScienceInduction

SCHWARTZ,R.

&

of

Med.

FELDMAN,agentsin

B8-Exptl.

Transplantation

W.,

mice.

&

hotnografts'E.

compe27:

180

Cancerandrats.

Cancermice.

817-834,

DBA/2

immunologic

sarcomaSurgery,

defense,20.

29.

vitaminthedefenseof

deficient

and

in

3.:

zymosanDependence

180

J. J. S. S.
'Host

regression

29:

E.:

J. J. S. S.

T.:
E.:

P.:

R.

Combination

cancerR.

transplanted

15.

19.

sarcoma

host,

28.

1964.

MIHICH,upon

methanol.-and; 652-654,

of

mice

the

FUGMANN,MCNEILL,B.W.:&

regressionoftubercleP.,mammary

Res.

27.

1969.

cyclophosphamide

spontaneous

deftcient18.

HAYWORTH,

with

FERRER,
the

a

16:

D.

CanCer
14.

of

' of

ENGLISH,,R.

aactionfractiontherapyonofImmunology, MARTIN,
A.,

mode

S.

antigens.

immunological&immunogenecity

insoluble

,13.

the

FRICHS,

skin

gens.

1039•`1065,

KRIEGBAUM,L.G.

Soc.

immunosuppressive'

1966.
12.

Proc.

unresponsiveness

HOEHN,
tailP.:

attenuated

124:

M.,

MC-

LESLIIE,

fraction

SELA,

Inst.

immunogenecity

methanol-insoluble

mice.

1971

1952.

immunologic

isografted

J.

in

im-

25;

BONHAG,
thenoma
128•`131,

1966.

D. W.,

StudiesJ.

1963,

carcinogencells.

505-512,ofofsarcomaWEISS,

carcinogenesis.
791-805,, Age-dependent,

effectmunodepression
induced31:

JULY

methotrexateW.

&

OWENS,

A.

production

in

the

treated

rat.

H.:

19 S

and

7 S

209:

622

cyclophosphamide
Nature

VOL.

39,

19

NO.

CHEMOITHERAPY

4

28:

〜624,

1966.

SAHIAR,K.

globulinsequence.

purine
or

and

319

&

SCHWARTZ,
I.

J.

The

Arrestbybyantibody,

restitution

splenectomy.

R.:

Immunol.

48.

immuno-6-mercaptoantigen,

49.

95:

BLINKOFF,
mice.

R.

globulin
746,

41.

42.

43.

44.

45.

46.

47.

C.: ƒÁM

Dissociation
sequence.

and ƒÁG

antibodies

of

the

normalJ.

Immunol.

inimmuno97:

50.

736〜

51.

transmission

Offrom man to man by the sternal
Cancer Res. 6: 695-698,
1946,

13:

389-394,

1953.

TOOLAN,
neoplasms

H. W.:
maintained

Transplantablehuman
in cortisone-treatedlaboratory

anirhals.

Cancer

GLYNN,

S. R.,

BIANCO,

A.

Res.

Res.

14:

660〜

1954.

immunity

53.

of
Med.

TOOLAN, H. W.: Growthof humantumorsincortisonetreatedlaboratory
animals.
Cancer666,
52.

Homotransplantation
Bull. N. Y. Acad.

34: 416-423,
1958.
THIERSCH, J. B.:
Attempted

Res.

1966.

BOREL, Y. & SCHWARTZ, R.: Inhibitionof
immediate and delayed hypersensitivity
by 6mercaptopurine.
J. ImMunol. 921: 754-761,
1964.
SWANSON,M. & SCHWARTZ, R.: Immunosuppresive therapy.
The relation between ,clinical response and immunologic
competence.
New Engl. J. Med. 277: 163-470, 1967.
MAIBACH,H.I. & EPSTEIN, W. L. Immunologic
responses
of healthy .volunteers
receivingazathiopurine.
Intern. Arch. Allergy 27: 102-109, 1965.
HERSH, E. M., CARBONE,P. P., WONG. V. G. &FREIREICH, E. M., CARBONE,P. P., WONG,V. G.
& FREIREICH, E. J.: Recovery of immune
responsiveness after drug suppression in man.
J. Lab. Clin. Med. 67: 566-572,
1966.
NATHAN, H. C., BIEBER, S., ELION, G. B. &HITCHING, G. H.: 'Detection of agents whichinterfere with the immune response.
Proc.
Soc. Exptl. Biol. Med. 107 796799,
1961.
MITCHELL, M., WADE, M., BERTINO, J. &CALABRESI,P.: Effects of cytosine arabinosideand methotrexate upon antibody synthesis anddelayed hypersensitivity
in man. Proc. Am.
Assoc. Cancer Res. 9: 50, 1968.
SCHWARTZ, R. S.: Are irnmunosuppressive
anticancer drugs self-defeating ? Cancer Res.

1968.

acte leukemia
marrowroute.

1965.
40.

1452-1454,

SOUTHAM, C. M.:
humancell lines.

HUMPHREYS, S:
R.

to
23:

&

GOLDIN,

leukemia

L 12101008-1015,

GOLDIN,A.

immunityin

L 1210.

&

J.

R.,

TRIVERS,A.:

Studies

in

G.,
on

mice.,

Cancer1963.
HUPHREYS,

mice

surviving

Natl.

CancerS. R.

StudiessystemicInst.

ofleukemia
24: 283•`300,

1960.
54.

DEODHAR,
P.F.:

55.

S. D.,

CRILE,

G.,

ImmunosuppressIontumoursystem.

MARTIN,D.

nologic

andships.

Lancet

S.

Jr.

in

_Cancer

&

Am.

Med.

murine1:168-470;

1968.

chemotherapy:.Immu-

chemotherapeuticJ.

SCHOFIELD,

allogeneic

interrelation-

Assoc:

128:723-726,

1961.
56.

MARTIN,

D.

S.

implications
size

and

Surg.
57.

of

151

interrelationships: 97-100,Y:

recurrence

6:19-25,

FUGMANN,thechemotherapeutic

MOLKOV;removal

&

of

R.

A.
of

response.

Ann.

1960.

N.:

Prevention

by

and

metastases

aftertransplantable
19,60.

tumor

tumors.

aurananofsurgical
Vop.

Onkol.